Transcript Document

SVOP
Applications, features and benefits
Best New Life Sciences Company in Scotland 2013
The SVOP: An Overview
 The SVOP is a Saccadic Vector Optokinetic




Perimeter
The SVOP is a visual field analyser invented at the
Royal Hospital for Sick Children in Edinburgh, UK
and commercialised by i2eye Diagnostics Ltd.
The SVOP was developed to meet a clinical need to
screen young children and those unable to perform a
standard visual field.
The SVOP is easy and intuitive to use by both
patients and operators. It can screen patients from
under one year old to over 70
The SVOP produces a standard visual field plot
familiar to all eye-care professionals.
How Does the SVOP Work?
 There is an introductory video to the SVOP on i2eye’s
website at: www.i2eyediagnostics.com
 The SVOP has an eye-tracker to continuously monitor
the patient’s gaze direction and distance from the
instrument. It uses this information to:
 Confirm their fixation,
 Accurately place target images within the central 30
degrees of their visual field and,
 Record their response by tracking their eye movement as
they react to the appearance of the target.
The SVOP Printout
The SVOP Patient Benefits
 Patient comfort
 Free head movement
 No head or chin rest
 No physical contact with the instrument
 Some movement allowed
 Concentration benefits
 Simple intuitive test, no complex instructions
 Response recorded objectively without considered feedback
from the patient
 Test normally complete within three minutes
Coverage of Conventional VF’s
 Conventional automatic
static perimeters can
screen approx. 60 % of the
population who are aged
between 10 and 70 years
and are neurologically
normal.
 Young children, the frail
elderly and those with
compromised neurological
function cannot be
screened reliably
Coverage of the SVOP
 The SVOP can screen
over 85% of the
population aged between
one and >70 years who
are neurologically
normal
 Infants and the frail
elderly can be screened
reliably
 A proportion of
neurologically
compromised subjects
can be tested
The SVOP Advantage
 The SVOP is a rapid automatic screening test suitable for
>90 % of neurologically normal subjects with normal eyes
 The SVOP is suitable for all ages from one to over 70 years
 A normal result has a 95% confidence level
 An abnormal or ambiguous result requires further
investigation




Low operator skill (nurse, technician etc)
Low patient stress
2 minute test
Central 30 degree field
Research Horizons
The correct
patient
No engagement
No calibration
Calibrates but is
unreliable
Calibrates and
tests
Understand current limitations
•
•
•
•
Neurologically intact with normal eyes 95% success
Brain tumours/discreet lesions approx. 50% success
Paediatric stroke approx. 30% success rates
Cerebral palsy <10% success
•
•
5-10% of patients will not look at or maintain engagement with the screen
Too few calibration points for accurate tracking
• Eyetracker line of sight blocked – hair, glasses, dry eyes, deep-set eyes
• Abnormal eye does not fit model – switch to KidzEyez or other method
•
30-50% of neurologically compromised patients give inconsistent results that are not
as anticipated
Condition specific normative data, analysis and interpretation necessary to improve
performance of SVOP- collaboration, Open Innovation
The patient must engage and calibrate
Principal research opportunities
•
•
•
•
•
Screening and testing
Screens 95% of the neurologically healthy population
Rapidly (2 minutes) identifies those who require further investigation
Frees resources to concentrate in areas of need
Ongoing internal and collaborative research is continually improving reach
Research Horizons for the SVOP
 SVOP is a new generation
of visual function tester.
 There are research
opportunities to improve
its reach into testing
severely neurologically
compromised individuals
 i2eye actively encourages
collaborative and thirdparty research through
Open Innovation
Key Users
Dr Gena Heidary
Dr Constance West
Mr Michael Clarke
Prof. Birgit Lorenz
Dr Luisa Mayer
Institution
Contact
role
Boston Children’s Hospital
Dr Gena Heidary
Director of Neuroophthalmology service
Cincinnati Children’s Hospital
Dr Constance West
Director of ophthalmology,
Associate Professor
Johns Hopkins Hostpital
Micheal Repka
Professor of Ophthalmology &
Pediatrics
Moorfields Eye Hospital
Ms Annegret Dahlmann-Noor
Consultant paediatric
ophthalmologist
Newcastle eye centre
Mr Michael Clarke
Consultant paediatric
ophthalmologist
Private practice, Paris
Dr Eliane DeLouvrier
Paediatric ophthalmologist
Ludwig-Maximilians-Universitt
Prof Birgit Lorenz
Paediatric ophthalmologist,
Head of Department, Chairman.
Availability
 SVOP is commercially available now in:
 Europe (CE marked class 2a medical device)
 Australia (TGA approved class 2a medical device)
 USA (FDA listed class 1 medical device exempt from 510(k)
 SVOP costs (POA) including:
 Delivery and training
 12 month warranty
 12 month software updates including those that enhance
performance or reach.
 Email and telephone support
 Ongoing maintenance contracts from Euro 1000 per year
Clinical References
Visual Field assessment in infants using Saccadic Vector Optokinetic Perimetry
BIPOSA 2013, invited verbal presentation, Brian Fleck
Saccadic Vector Optokinetic Perimetry (SVOP): A novel technique for automated static perimetry in children using eye
tracking.
Murray I, Perperidis A, Brash H, Cameron L, McTrusty A, Fleck B, Minns R.
Conf Proc IEEE Eng Med Biol Soc. 2013;2013:3186-9. doi: 10.1109/EMBC.2013.6610218.
PMID: 24110405 [PubMed - in process]
Visual field measurement in infants and young children with neurological disorders using saccadic vector optokinetic
perimetry (SVOP).
Brian W. Fleck, Ian Murray, Harry Brash, Robert Minns
Journal of AAPOS February 2012 (Vol. 16, Issue 1, Page e5)
Feasibility of saccadic vector optokinetic perimetry: a method of automated static perimetry for children using eye
tracking.
Murray IC, Fleck BW, Brash HM, Macrae ME, Tan LL, Minns RA.
Ophthalmology. 2009 Oct;116(10):2017-26. doi: 10.1016/j.ophtha.2009.03.015. Epub 2009 Jun 27.
PMID: 19560207 [PubMed - indexed for MEDLINE]
093: Automated visual field assessment in young children using eye tracking—preliminary data from 9 children
Ian C. Murray, Mary E. MacRae, Brian W. Fleck, Harry M. Brash, Lai L. Tan, Robert A. Minns
Journal of AAPOS February 2009(Vol. 13, Issue 1,Page e24)
Contact
i2eye Diagnostics ltd
9 Edinburgh BioQuarter
Little France
Edinburgh
EH16 4UX
UK
T: +44 (0) 131 658 5154
E: [email protected]
W: www.i2eyediagnostics.com
In the USA
Steve Elfrink: [email protected]
Phone: 608-632-0914